Literature DB >> 34150939

In vivo CD40 Silencing by siRNA Infusion in Rodents and Evaluation by Kidney Immunostaining.

Miguel Hueso1, Adrián Mallén2, Elia Ripoll2, Laura de Ramón2, Núria Bolaños2, Cristian Varela2, Jordi Guiteras2, Javier Checa3, Estanislao Navarro4, Josep Maria Grinyo5, Josep Maria Cruzado1,5, Josep Maria Aran3, Joan Torras1,5.   

Abstract

The co-stimulatory molecule CD40 and its ligand CD40L play a key role in the regulation of immunological processes and are involved in the pathophysiology of autoimmune and inflammatory diseases. Inhibition of the CD40-CD40L axis is a promising therapy, and a number of strategies and techniques have been designed to hinder its functionality. Our group has broad experience in silencing CD40 using RNAi technology, and here we summarize protocols for the systemic administration of a specific anti-CD40 siRNA in different rodents models, in addition to the subsequent quantification of CD40 expression in murine kidneys by immunostaining. The use of RNAi technology with specific siRNAs to silence genes is becoming an essential method to investigate gene functions and is rapidly emerging as a therapeutic tool. Graphic abstract: CD40 siRNA mechanism.
Copyright © 2021 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  CD40; CD40L; Cholesterol-derived oligonucleotide; Kidney; Off-target effects; siRNA; siRNA therapy

Year:  2021        PMID: 34150939      PMCID: PMC8187154          DOI: 10.21769/BioProtoc.4032

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  16 in total

1.  Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference.

Authors:  Kumiko Ui-Tei; Yuki Naito; Fumitaka Takahashi; Takeshi Haraguchi; Hiroko Ohki-Hamazaki; Aya Juni; Ryu Ueda; Kaoru Saigo
Journal:  Nucleic Acids Res       Date:  2004-02-09       Impact factor: 16.971

2.  The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides.

Authors:  Rosel Kretschmer-Kazemi Far; Georg Sczakiel
Journal:  Nucleic Acids Res       Date:  2003-08-01       Impact factor: 16.971

Review 3.  Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond.

Authors:  Jodi L Karnell; Sadiye Amcaoglu Rieder; Rachel Ettinger; Roland Kolbeck
Journal:  Adv Drug Deliv Rev       Date:  2018-12-13       Impact factor: 15.470

4.  Silencing of CD40 in vivo reduces progression of experimental atherogenesis through an NF-κB/miR-125b axis and reveals new potential mediators in the pathogenesis of atherosclerosis.

Authors:  Miguel Hueso; Laura De Ramon; Estanislao Navarro; Elia Ripoll; Josep M Cruzado; Josep M Grinyo; Joan Torras
Journal:  Atherosclerosis       Date:  2016-11-02       Impact factor: 5.162

5.  Quantification of Atherosclerosis in Mice.

Authors:  Monica Centa; Daniel F J Ketelhuth; Stephen Malin; Anton Gisterå
Journal:  J Vis Exp       Date:  2019-06-12       Impact factor: 1.355

Review 6.  The Use of Anti-CD40 mAb in Cancer.

Authors:  Marcus Remer; Ann White; Martin Glennie; Aymen Al-Shamkhani; Peter Johnson
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

7.  The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript.

Authors:  Erin A Bohula; Amanda J Salisbury; Muhammad Sohail; Martin P Playford; Johann Riedemann; Edwin M Southern; Valentine M Macaulay
Journal:  J Biol Chem       Date:  2003-02-24       Impact factor: 5.157

8.  CD40 gene silencing reduces the progression of experimental lupus nephritis modulating local milieu and systemic mechanisms.

Authors:  Èlia Ripoll; Ana Merino; Immaculada Herrero-Fresneda; Josep M Aran; Montse Goma; Nuria Bolaños; Laura de Ramon; Oriol Bestard; Josep M Cruzado; Josep M Grinyó; Juan Torras
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

9.  Free radical scavenging property and diuretic effect of triglize, a polyherbal formulation in experimental models.

Authors:  S Parasuraman; Ep Kumar; Anil Kumar; Sf Emerson
Journal:  J Pharmacol Pharmacother       Date:  2010-01

10.  Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes.

Authors:  A Arranz; C Reinsch; K A Papadakis; A Dieckmann; U Rauchhaus; A Androulidaki; V Zacharioudaki; A N Margioris; C Tsatsanis; S Panzner
Journal:  J Control Release       Date:  2012-11-21       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.